ONCOZEN

ONCOZEN is a South Korean biotechnology company founded in 2020 that specializes in the development of innovative oncology therapies and treatments for rare diseases. The company's core technology is its proprietary Chaperone-Mediated Protein Degradation (CMPD) platform, which utilizes the body's ubiquitin-proteasome system to selectively and efficiently degrade disease-causing proteins. ONCOZEN's lead candidate, OZ-001, is a dual-targeting small molecule that inhibits both T-type calcium channels and the STAT3 signaling pathway, currently undergoing preclinical toxicity studies for indications including non-small cell lung cancer and pancreatic cancer. The company is also advancing a diverse pipeline of CMPD-based degraders targeting c-Met, Tau, and other oncogenic drivers. Headquartered in Cheongju, ONCOZEN maintains multiple R&D centers and has established strategic partnerships, such as its collaboration with Wellmarker Bio, to accelerate the translation of its platform into first-in-class medicines.